Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00056654 · ClinicalTrials.gov registry record · NA
Study of a 6-Month Sustained-Release Formulation of Leuprolide Acetate in Prostate Cancer
A NA study, sponsored by Abbott.
- Completed
- Registry status
- NA
- Development phase
- 164
- Enrollment target
NCT00056654 is a NA study that has completed, run by Abbott. The registered enrollment target is 164 participants.
The verdict
NCT00056654, a NA study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- NA
- Development phase
- 164 participants
- Enrollment target
Study Summary
The primary purpose of the study is to determine if a new sustained-release 45 mg (depot) formulation of leuprolide acetate will reduce serum testosterone levels to and maintain them at medically castrate levels in subjects with prostatic adenocarcinoma.
Interventions
- DRUG Leuprolide acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 164 participants |
| Start Date | 2003-03 |
| Est. Completion | 2004-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00056654
The ClinicalTrials.gov registry entry for NCT00056654 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 164 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Leuprolide acetate is the first listed.
NCT00056654 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00056654 about?
NCT00056654 is a clinical study titled "Study of a 6-Month Sustained-Release Formulation of Leuprolide Acetate in Prostate Cancer". The primary purpose of the study is to determine if a new sustained-release 45 mg (depot) formulation of leuprolide acetate will reduce serum testosterone levels to and maintain them at medically castrate levels in subjects with prostatic adenocarcinoma.
What is the current status of trial NCT00056654?
This trial is currently completed. It is a NA study. The enrollment target is 164 participants. The study started on 2003-03. Estimated completion is 2004-07.
What interventions are being tested in trial NCT00056654?
The interventions under investigation include: Leuprolide acetate (DRUG).
Who is sponsoring clinical trial NCT00056654?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.